BRIEF published on 11/10/2025 at 18:10, 24 days 12 hours ago Ascend's Innovation Enhances AAV Production Efficiency Gene Therapy Biotechnology Innovation Ascend Advanced Therapies AAV Production Manufacturing Enhancers
BRIEF published on 11/10/2025 at 18:10, 24 days 12 hours ago L'innovation d'Ascend améliore l'efficacité de la production d'AAV Thérapie Génique Innovation En Biotechnologie Ascend Advanced Therapies Production AAV Améliorants De Fabrication
PRESS RELEASE published on 11/10/2025 at 18:05, 24 days 12 hours ago Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality Ascend Advanced Therapies unveils proprietary enhancers demonstrating significant improvements in AAV yields and quality attributes for gene therapy programs Ascend Advanced Therapies Proprietary Enhancers AAV Yields Gene Therapy Programs Quality Attributes
BRIEF published on 10/08/2025 at 15:10, 1 month 27 days ago Ascend Advanced Therapies Successfully Defends EpyQ® Patent at EPO Intellectual Property Gene Therapy European Patent Office Ascend Advanced Therapies EpyQ® AAV Plasmid
BRIEF published on 10/08/2025 at 15:10, 1 month 27 days ago Ascend Advanced Therapies défend avec succès le brevet EpyQ® auprès de l'OEB Propriété Intellectuelle Thérapie Génique Office Européen Des Brevets Thérapies Avancées Ascend Plasmide AAV EpyQ®
PRESS RELEASE published on 10/08/2025 at 15:05, 1 month 27 days ago European Patent on Ascend Advanced Therapies' EpyQ® AAV Plasmid Technology Successfully Defended at the EPO Ascend Advanced Therapies successfully defends European patent EP3722434 for EpyQ® AAV plasmid technology at the EPO, reinforcing its position in gene therapy Gene Therapy European Patent Ascend Advanced Therapies EpyQ® AAV Plasmid Technology
Published on 12/05/2025 at 02:35, 4 hours 1 minute ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 36 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 31 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 36 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 6 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 46 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 11 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 21 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 26 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:14, 12 hours 22 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 12 hours 36 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 12 hours 36 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 51 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 12 hours 51 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
